Edition:
United Kingdom

People: Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

8.38USD
15 Jul 2019
Change (% chg)

$-0.12 (-1.41%)
Prev Close
$8.50
Open
$8.46
Day's High
$8.46
Day's Low
$8.29
Volume
25,768
Avg. Vol
56,641
52-wk High
$14.35
52-wk Low
$6.20

Hetherington, Andrew 

Mr. Andrew Hetherington is Vice President - Manufacturing Operations of Catalyst Biosciences, Inc. Mr. Hetherington brings to Catalyst Biosciences more than two decades of experience in global commercial and clinical manufacturing, technology transfer and product development. Mr. Hetherington previously served as the Head of Immuno Manufacturing at the Diagnostics division of Novartis, where he worked from April 2010 until August 2015 and was responsible for providing recombinant and finished product for Novartis' $400 million blood testing business. Prior to Novartis, from 1998 to 2010, Mr. Hetherington held various key Manufacturing positions at Bayer Healthcare's Biotechnology Division, with the most recent being the Head of New Products and Contract Manufacturing where he was responsible for manufacturing Bayer's commercial recombinant Factor VIII and clinical stage replacements to supply the company's global $1 billion annual business. At Bayer, Mr. Hetherington also held the positions of Director of Manufacturing for the Purification and Plasma group as well as Senior Production Manager of Fermentation, Purification and Plasma. Prior to Bayer, Mr. Hetherington was a Production Manager of Solid Dose Manufacturing and Packaging at Glaxo Wellcome's Pharmaceutical Division.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --